Picture [iito] Fighting Customers 650x80px
Document › Details

Monte Rosa Therapeutics, Inc.. (6/23/21). "Press Release: Monte Rosa Therapeutics Announces Pricing of Initial Public Offering". Boston, MA.

Region Region United States (USA)
Organisations Organisation Monte Rosa Therapeutics Inc. (Nasdaq: GLUE)
  Group Monte Rosa Therapeutics (Group)
  Organisation 2 Nasdaq Global Select Market
  Today Nasdaq Global Market
  Group Nasdaq OMX (Group)
Products Product QuEEN™ protein degradation platform
  Product 2 investment banking
Index term Index term Monte Rosa Therapeutics–SEVERAL: investment, 202106 IPO $222.3m+$33.345m with 11.7m+1.755m shares common stock at Nasdaq Global Select Market
Persons Person Graziano, John (Trout Group 201609)
  Person 2 Budwick, Dan (1AB Media 201704– Founder before Pure Communications)

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins, today announced the pricing of its initial public offering of 11,700,000 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by Monte Rosa. The shares are expected to begin trading on the Nasdaq Global Select Market on June 24, 2021 under the ticker symbol “GLUE.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Monte Rosa, are expected to be approximately $222.3 million. The offering is expected to close on June 28, 2021, subject to the satisfaction of customary closing conditions. In addition, Monte Rosa has granted the underwriters a 30-day option to purchase up to an additional 1,755,000 shares of common stock at the initial public offering price.

J.P. Morgan Securities LLC, Cowen, Piper Sandler and Guggenheim Securities, LLC are acting as joint book-running managers for the offering.

A registration statement relating to these securities became effective on June 23, 2021. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone at (866) 803-9204, or via email at; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at or by telephone at (833) 297-2926; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924, or via email:; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Monte Rosa

Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™, that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.


John Graziano, Solebury Trout


Dan Budwick, 1AB

Record changed: 2021-07-21


Picture [iito] Made Without Love 650x80px

More documents for Monte Rosa Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2021 Time to Register 650x300

» top